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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
To assess the eects of interventions to enhance adherence to airway clearance treatment and exercise therapy in people with CF and their
eects on health outcomes, such as pulmonary exacerbations, exercise capacity, health-related QoL and healthcare costs.
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B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is a life-limiting autosomal recessive genetic
disorder, which aects exocrine glands (predominantly lungs and
pancreas) throughout the body. A genetic mutation aecting the
CF membrane trans-regulator protein (CFTR) acts on chloride
channels, leading to excessive reabsorption of sodium and water
across cell membranes; this produces dehydrated extracellular
fluid and subsequently thick secretions (Ratjen 2009). In the
lungs, airway liquid depletion impairs mucociliary transport,
making thick secretions diicult to clear; these accumulate causing
repeated respiratory tract infection, poor mucociliary clearance,
persistent bacterial colonisation and irreversible damage (Hurt
2012). Indeed, respiratory failure is the predominant cause of
morbidity and mortality in CF (Radtke 2017). Consequences of
progressive respiratory disease (productive cough, haemoptysis,
breathlessness and reduced exercise capacity) (Bott 2009), plus
pancreatic insuiciency characterised by poor absorption of
protein and fat (Ratjen 2009), with subsequent malnutrition
(O'Sullivan 2009), result in a reduced quality of life (QoL) (Britto
2004; Dobbin 2005).
Physiotherapy is an integral and essential component for
managing CF (Bott 2009; CF Trust 2017; NICE 2017). Physiotherapy
may comprise multimodal interventions, e.g. the management
of musculoskeletal conditions and stress urinary incontinence
(Button 2016); however, the cornerstone of treatment (and
therefore the focus of this review) involves the assessment
and management of cardiovascular capacity (exercise) (Radtke
2017), and airway clearance (Sherman 2019; Wilson 2019) with or
without the use of non-invasive ventilation (Moran 2017). There
is significant variation in the range of physiotherapy management
options for people with CF, but the treatment regimen is invariably
acknowledged as burdensome for the patient and carer(s) across
the course of their life. The median number of treatments per
day for an adult with CF is seven, which constitutes an average
daily treatment duration of between 108 min to three hours
(Dodd 2000; Sawicki 2009). Consequently, given the reported
time burden, non-adherence to physiotherapy is an ongoing
challenge in the treatment of CF (O'Donohoe 2014). Self-reported
adherence to airway clearance in adults with CF is approximately
30% (Meyers 2006), with a documented decline of up to 50% in
adherence in adolescence (Arias Llorente 2008). Non-adherence to
exercise (defined as planned, structured, and repetitive physical
activity with the aim of improving or maintaining physical
fitness (Casperson 1985)) has also been described; however, it
is suggested that the perception of exercise therapy is generally
viewed more positively by individuals with CF given its focus on
health promotion rather than illness management (Rand 2014).
Factors such as the impact on activities of daily living and
social functioning, treatment burden, accidental or purposeful
forgetting, no perceived benefit of and "being unpleasant" have
been identified as influencing non-adherence (Arias Llorente
2008; Conway 1996; Dodd 2000; George 2010). Poor adherence
to all aspects of CF treatment has been associated with an
increased number of infective pulmonary exacerbations and the
need for intravenous (IV) antibiotic therapy (Eakin 2011). The
consequences of poor physiotherapy adherence are significant
both for individuals with CF (reduced QoL, malaise and mortality)
and in terms of healthcare costs (Wildman 2014).
Description of the intervention
Individuals with CF require an extensive, complex treatment
regimen focused on medication, airway clearance techniques
and exercise participation (Bott 2009; NICE 2017). Adherence is
defined as "the extent to which a person's behaviour (i.e. taking
medication, following a diet and/or executing lifestyle changes),
corresponds with agreed recommendations from a healthcare
provider" (WHO 2003). Adherence and persistence to treatment in
CF varies by specific intervention; adherence is generally poorer
for ACT when compared to most medication use (Myers 2006).
Poor adherence to physiotherapy has been estimated to be about
60% (Bregnballe 2011); it leads to an increase in episodes of
acute infection and hospital admission, which may contribute
to premature death (Meyers 2006). Barriers to physiotherapy
adherence in people with CF are multifactorial (Abbott 1994;
Bregnballe 2011; Conway 1996; Geiss 1992; George 2010; Sawicki
2009), in particular the high time-demand of daily management
is evidenced (Arias Llorente 2008; Bernard 2004; Bregnballe 2011).
Although adherence to physiotherapy treatment varies between
individuals, it is particularly poor in adolescents and young adults
with CF (Arias Llorente 2008; Bregnballe 2011; Conway 1996;
Eakin 2011; George 2010; O'Donohoe 2014). Clinical variables (e.g.
disease severity), demographic characteristics and knowledge for
the condition have not been demonstrated as reliable predictors
of treatment adherence (Sherman 2019). Contemporary work has
considered the application of social cognitive theory, in particular
the influence of psychosocial variables such as self-eicacy and
self-confidence in overcoming barriers to treatment components,
as well as the influence of subjective norms (Bishay 2016; George
2010; Sherman 2019).
Interventions that aim to enhance adherence to physiotherapy
in people with CF may improve functional and health-
related QoL; these include psycho-educational interventions
(leaflets, videos, apps aimed at increasing knowledge and
understanding), psychotherapeutic or motivational interventions
(cognitive behavioural therapy (CBT), contingent privileges or
rewards, setting realistic expectations, motivational interviewing),
or organisational interventions (self-management diary, electronic
reminders, technology-based interventions such as active gaming,
apps, tele-care) (Du 2010). Evaluation of these strategies will
provide evidence to inform clinical practice and improve healthcare
outcomes for people with CF.
How the intervention might work
The development of complex prophylactic management and
treatment options for symptomatic relief has led to an increased
median predicted survival age from young childhood to over
40 years of age (Preston 2014); however, although adherence to
these interventions is essential for eicacy (Eakin 2011; Sawicki
2009), adherence to physiotherapy airway clearance techniques
and exercise remains lower than other treatments (Meyers 1999).
Identifying patient-reported barriers to treatment adherence
has been considered essential for developing approaches
targeted at modifiable factors (Sherman 2019). Psycho-educational
interventions target knowledge and understanding of the condition
and treatment benefits and barriers; some studies have suggested
that there are significant gaps in knowledge across people
with CF and their families (Lonabaugh 2018), or that the
information is suppressed as part of an individual's coping style
(Du 2010). Psychotherapeutic and motivational approaches are
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broadly aimed at reducing stress, improving coping styles and
strategies, and exploring ambivalence or enhancing behaviour
change in favour of adherence to the prescribed treatment
regimen (Goldbeck 2014). Organisational interventions assist in the
organisation and time management of treatments, e.g. providing
active reminders or prompts, scheduling strategies, or tailoring
treatments to lifestyle or life-stage, e.g. encouraging exercise
through active video gaming.
Why it is important to do this review
Physiotherapy is generally considered to be an integral and
essential component of the management of CF (Bott 2009; NICE
2017). The consequences of poor physiotherapy adherence may
be potentially significant both for individuals with CF (repeated
respiratory infection, reduced exercise tolerance, breathlessness,
reduced QoL, malaise and reduced life expectancy) and in terms
of healthcare costs (increased use of pharmacology, GP access
and hospital admission). As such, evidence-based strategies to
inform clinical practice and improve adherence to physiotherapy
management are believed to be significant for improving QoL
for the individual and reducing economic burden; this area of
research has been raised as a priority by the James Lind Alliance
Priority Cystic Fibrosis Setting Partnership (Rowbotham 2019). The
need to assess the eicacy of strategies to improve adherence
to physiotherapy management is of paramount importance to
optimise healthcare outcomes.
O B J E C T I V E S
To assess the eects of interventions to enhance adherence
to airway clearance treatment and exercise therapy in people
with CF and their eects on health outcomes, such as
pulmonary exacerbations, exercise capacity, health-related QoL
and healthcare costs.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We plan to include randomised controlled trials (RCTs) and quasi-
RCTs. Observational studies, case studies and cross-over RCTs will
not be eligible for inclusion.
Types of participants
Adults and children (from aged eight years upwards) with
CF; the lower limit of eight years is based on the age at
which specialist units expect children with CF to manage their
physiotherapy independently (with potential supervision, but not
active involvement, of parents). We will include populations of
either gender, any ethnicity, any stage of disease and based in either
a hospital or community setting.
Types of interventions
We plan to include any intervention aimed at enhancing adherence
to physiotherapy versus no intervention, usual care or another
intervention aimed at enhancing adherence to physiotherapy.
We will not compare adherence to two dierent physiotherapy
regimens.
Interventions may include:
• educational (increasing knowledge and understanding);
• behavioural (CBT, contingent privileges or rewards, setting
realistic expectations);
• organisational (self-management diary, electronic reminders);
or
• technology (active gaming, apps, tele-care).
We plan to evaluate adherence using these interventions to one or
more of the following components of physiotherapy management;
cardiovascular capacity (exercise) with or without the use of non-
invasive ventilation, and airway clearance with or without the use
of non-invasive ventilation.
Types of outcome measures
Primary outcomes
1. Adherence
a. electronic monitoring (% of completed treatments)
b. confirmed observed participation by parent or carer or
healthcare professional (% of completed treatments)
c. self-reported diary (% of completed treatments)
Secondary outcomes
1. Frequency of hospitalisation for respiratory infection
(requirement for non-routine IV antibiotics)
2. Frequency of non-hospitalised respiratory infection
(requirement for home unplanned, rescue or non-routine IV
antibiotics)
3. Lung function
a. forced expiratory volume at one second (FEV1) (L and %
predicted)
b. forced vital capacity (FVC) (L and % predicted)
c. FEV1/FVC %
d. lung clearance index (LCI)
4. QoL measures using a disease-specific tool (e.g. Cystic fibrosis
Health-Related Quaility of Life questionnaire (Quittner 2005)) or
a non-specific tool (SF36)
5. Adverse events (any adverse advent associated with
the intervention reported by authors (e.g. haemoptysis,
pneumothorax, respiratory distress, death)
6. Exercise capacity
a. shuttle walking test
b. 6-minute walk
c. step test
d. cardio-pulmonary exercise testing (CPET) and VO2 peak
We will compare data between the intervention and control group
at the end of the intervention period, plus the end of intervention
and any follow-up period. We will report data from three time-
periods: immediate or short term (less than one month); medium
term (one to six months); and long term (greater than six months).
Search methods for identification of studies
There will be no restrictions regarding language or publication
status.
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Electronic searches
The Cochrane Cystic Fibrosis and Genetic Disorders Group's
Information Specialist will conduct a systematic search of the
Group's Cystic Fibrosis Trials Register for relevant studies using the
following terms: physiotherapy AND treatment adherence.
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of the Cochrane Library),
weekly searches of MEDLINE, a search of Embase to 1995 and the
prospective handsearching of two journals - Pediatric Pulmonology
and the Journal of Cystic Fibrosis. Unpublished work is identified
by searching the abstract books of three major cystic fibrosis
conferences: the International Cystic Fibrosis Conference; the
European Cystic Fibrosis Conference and the North American Cystic
Fibrosis Conference. For full details of all searching activities for
the register, please see the relevant section of the Cochrane Cystic
Fibrosis and Genetic Disorders Group's website.
We will additionally search the following electronic databases to
identify published articles and additional studies for inclusion in
this review.
• MEDLINE Ovid (1946 to present)
• SCOPUS Elsevier (1823 to present)
• AMED EBSCO (Allied and Complementary Medicine; 1985 to
present)
• PsychINFO APA Publishing (1806 to present)
• CINAHL EBSCO (Cumulative Index to Nursing and Allied Health
Literature; 1982 to present)
• LILACS (Latin American and Caribbean Health Science
Information database (www.bireme.br); 1982 to present)
We will also search online trials registries:
• the WHO International Clinical Trials Registry Platform
(apps.who.int/trialsearch);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov);
• ISRCTN registry (www.isrctn.com);
• HSRProj (Health Services Research Projects in Progress (//
hsrproject.nlm.nih.gov/).
The database search strategies can be found in the appendices
(Appendix 1).
Searching other resources
We will check the bibliographies of included studies and any
relevant systematic reviews identified for further references to
relevant studies.
We plan to search the following conference proceedings (last 10
years where available):
• American Thoracic Society (ATS) International Conference
(www.thoracic.org);
• European Respiratory Society (ERS) International Congress
(www.ersnet.org);
• British Thoracic Society (summer and winter meetings)
(www.brit-thoracic.org.uk);
• UK Cystic Fibrosis Conference (UKCFC)
(www.cysticfibrosis.org.uk).
Data collection and analysis
Selection of studies
Two review authors (MOJ and FM) will independently check search
results for eligible studies. Initially, both authors will screen the
titles and abstracts of identified studies. If it is clear from the
study title or abstract that the study is not relevant or does
not meet the selection criteria, we will exclude it. If eligibility is
unclear, then we will retrieve the full paper and assess this; we
will also retrieve full papers for all studies that appear to meet the
selection criteria. Both authors will also assess non-English papers
and if necessary, translate these with the assistance of a native
speaker. We will resolve any disagreement through discussion and
consensus. Where we do not achieve resolution, a third author (AH)
will consider the paper(s) in question (Higgins 2011). We will keep a
full record of decisions and their rationale. We will contact experts
and organisations in the field to obtain additional information on
relevant trials.
Data extraction and management
Two review authors (MOJ and FM) will independently extract
data using a standardised form. We will resolve discrepancies by
consensus; if we are unable to reach agreement, a third author (AH)
will consider the paper.
The form will include:
• study design;
• sample size (intervention and control groups);
• country of origin;
• study population (age, gender);
• details of the intervention (educational (increasing knowledge
and understanding); behavioural (CBT, contingent privileges
or rewards, setting realistic expectations); organisational (self-
management diary, electronic reminders); or technology (active
gaming, apps, tele-care)
• results for outcomes (primary and secondary outcomes as
described above) and adverse events split by time point;
• risk of bias assessments.
Where papers do not present suicient data to enter a study into
the meta-analysis, we will contact study authors to request access
to the missing data.
We will compare data between the intervention and control group
at the end of the intervention period, plus the end of intervention
and any follow-up period. We will report data from all time-periods,
e.g. immediate or short term (less than one month); medium term
(one to six months); and long term (greater than six months).
Where studies report multiple measures, we will use data taken
at the time-point closest to these thresholds. If the studies use
multiple interventions we will summarise the results for outcomes
separately. We will look at the eect of any intervention on the
adherence to ACT and the adherence to exercise separately; we
will analyse and present the comparisons of dierent interventions
separately.
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Assessment of risk of bias in included studies
Two review authors (MOJ and FM) will independently assess the
risk of bias (ROB) in included studies using the Cochrane ROB
assessment tool outlined in chapter 8 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2017). Where we
disagree, we will resolve dierences through discussion and if we
do not achieve resolution for the paper(s) in question, a third
author (AH) will consider the judgement. Where the quality of
studies is unclear, we will attempt to contact the study authors for
clarification.
We will assess ROB based on Cochrane criteria, summarising ROB
for each outcome of interest within a study.
We will assess the following criteria (using yes, no or unclear
judgements).
• Adequate sequence generation?
• Adequate allocation concealment?
• Adequate blinding of assessors?
• Incomplete outcome data adequately assessed?
• Free of suggestion of selective outcome reporting?
• Free of other bias?
It may be possible that therapists or clinicians will not be blinded
in all studies of this kind of intervention; in this situation we will
not assess these criteria, but will reflect the potential impact of
incomplete blinding in the discussion of the results.
Measures of treatment e9ect
For continuous variables (adherence (% of completed treatments),
hospital admission (frequency and duration), non-hospitalised
infection (frequency and duration), lung function tests and
QoL) we will use the pooled mean dierence (MD) with 95%
confidence intervals (CIs) as the measure of treatment eect.
Where dierent studies have used a variety of measures, we will
use the standardised mean dierence (SMD) with 95% CIs to
report the pooled treatment eect. We will use the mean (and
standard deviation (SD)) post-intervention for each group in the
meta-analyses. Where these data are unavailable, we will use
the the mean (and SD) change from baseline for each group.
For dichotomous outcomes (adherence (confirmed observed
participation) and reported adverse events), we will use the pooled
risk ratio (RR) as the measure of treatment eect.
Unit of analysis issues
Where studies report multiple measures, we will use data taken at
the time-point closest to our stated thresholds (see above). If the
studies use multiple interventions, we will summarise the results
for outcomes separately. We will analyse and present comparisons
of dierent interventions separately. An included study may be
designed such that investigators compare two dierent adherence
interventions against a control group, but it is likely the two
arms will have dierent participants; we will analyse the two
interventions separately. If the participants are the same for both
arms, this may result in double-counting.
The unit of analysis will be the participant; cross-over studies are
not eligible for inclusion in the review.
Dealing with missing data
Where insuicient data are available to enter a study into a meta-
analysis, we will contact the study authors to request access to
the missing data. We will not impute missing data. Where data are
missing and we can not obtain these from the study authors, we will
acknowledge this as a limitation.
Assessment of heterogeneity
We will assess heterogeneity and its impact using the Chi2
test and the I2 test (Deeks 2017). We will interpret I2 values
of approximately 30% to 75% as moderate heterogeneity and
values over 75% as substantial heterogeneity. However, we will
interpret the importance of observed I2 values with reference to the
magnitude of eects and the strength of evidence for heterogeneity
as obtained from the Chi2 test.
Assessment of reporting biases
We will report on selective outcome reporting as detailed in
Assessment of risk of bias in included studies. Where suicient
data are available (i.e. at least 10 studies), we will explore possible
publication bias and small study eects using funnel plots and test
for funnel plot asymmetry using Egger’s test.
Data synthesis
Where suicient data are available, we will pool data for each
outcome using a random-eects meta-analysis. We will conduct
separate meta-analyses to examine eects of: (1) interventions
to improve adherence to airway clearance treatment; and (2)
interventions to improve adherence to exercise, compared to
no treatment or usual care. Where studies examine eects of
multiple interventions, we will include participants from each
arm in separate meta-analyses. We will used a random-eects
model as we expect there to be variation between studies in
terms of participants and interventions. Where suicient data are
not available for a given outcome we will describe the findings
narratively.
Subgroup analysis and investigation of heterogeneity
We plan to undertake a subgroup analysis according to age, i.e.
children (8 to 12 years of age), adolescents (12 to 18 years) and
adults (18 years and over), if the available data allow. Where studies
include children and adolescents (e.g. 8 to 18 years) or adolescents
and adults (e.g. 12 years and over), and we are unable to extract
data for each age group, we will conduct separate subgroup
analyses for children and adolescents, or adolescents and adults.
Sensitivity analysis
Where suicient data are available, we will conduct sensitivity
analyses on the basis of risk of bias, specifically the eect of
excluding studies at overall high risk of bias. We will define overall
high risk of bias as having a judgement of a high risk of bias against
at least one criteria.
Summary of findings and assessment of the certainty of the
evidence
The 'Summary of findings' tables will provide key information
concerning the quality of evidence, the magnitude of eect of
the interventions examined, and the sum of available data on
all important outcomes for a given comparison (Schünemann
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2017a). This will provide patient-important outcomes for decision
making by healthcare professionals and caregivers. We will use the
GRADE approach to evaluate the literature and reflect the extent
to which we are confident that an estimate of the eect is correct
(Schünemann 2017b). We will generate a table for each comparison
that is presented in the review (Appendix 2), and where data allow
we will undertake a subgroup analysis based on age. The outcomes
presented in each table will include, in order of priority:
1. adherence to treatment (% completed treatments) (reported
using SMD for all results combined in the medium term (from
one to six months));
2. frequency of hospitalisation in the medium term (from one to six
months);
3. frequency of non-hospitalised respiratory infection in the
medium term (from one to six months);
4. change from baseline in exercise capacity (by either shuttle
walking test, 6-minute walk, Step Test or CPET) (reported using
SMD for all results combined in the medium term (from one to
six months));
5. change from baseline in QoL (using a disease-specific tool (e.g.
Cystic Fibrosis Quality of Life Questionnaire) or a non-specific
tool (SF36) (reported using SMD for all results combined in the
medium term (from one to six months));
6. change from baseline in FEV1, % predicted (medium term (from
one to six months);
7. change fro baseline in FVC % predicted (medium term (from one
to six months).
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A P P E N D I C E S
Appendix 1. Additional electronic search strategies
 
Database Date(s) searched Search strategy
Scopus Elsevier 1823 to date 1 cystic fibrosis OR mucoviscidosis OR mucoviscidose [Article title, Abstract, Keywords]
2 adhere OR adherence OR adhered OR nonadherence OR persist OR persistance OR per-
sisted OR compliance OR comply OR complied OR noncompliance OR concordance OR
nonconcordance OR cooperative OR cooperation OR cooperate OR cooperated OR unco-
operative OR conform
3 Psycho* OR behavio* OR attitude* OR communicat* OR reward* OR remind* OR edu-
cat* OR supervis* OR famil* OR train* OR monitor* OR problem* OR team* OR diar* OR
counsel* OR feedback OR reinforc* OR motivat* OR self-regulat* OR cope OR coping OR
emotion*
4 social* OR socio* OR cognitive OR mental* OR verbal* OR condition* OR knowledge
OR personal OR construct OR crisis OR aversion OR assertiv* OR Accept* OR commit* OR
mind* OR mood* OR support* OR well* OR habit* OR talk* OR depress*
5 technology OR app* OR telehealth OR telecare OR telemedicine OR interactive OR mo-
bile OR web OR internet OR online OR game OR games OR gaming OR text OR messag* OR
telemonitoring OR chip OR chipped OR tracking OR tracker OR digital OR Bluetooth OR
video
6 smartphone OR iphone OR ipad OR electronic OR computer OR reward* OR schedul*
OR telerehab*
7 #3 OR #4 OR #5 OR #6
8 physiotherap* OR exercis* OR “non-invasive ventilation” OR NIV OR “airway clearance”
9 #1 AND #2 AND #7 AND #8
*NOTE: maximum number of characters exceeded in Line #3, so intervention search terms
divided into four search lines and combined using OR operator (Line #7)
Medline Ovid 1946 to date Search terms to be based on Scopus search strategy
PsychINFO APA
Publishing
1806 to date Search terms to be based on Scopus search strategy
CINHAL EBSCO
(Cumulative Index
to Nursing and Al-
lied Health Litera-
ture)
1982 to date Search terms to be based on Scopus search strategy
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1985 to date [Advanced Search]
cystic fibrosis OR mucoviscidosis OR mucoviscidose [Title, abstract, subject]
AND
adhere OR adherence OR adhered OR nonadherence OR persist OR persistance OR per-
sisted OR compliance OR comply OR complied OR noncompliance OR concordance OR
nonconcordance OR cooperative OR cooperation OR cooperate OR cooperated OR unco-







1982 to date [Advanced Search]
cystic fibrosis OR mucoviscidosis OR mucoviscidose [Title, abstract, subject]
AND
adhere OR adherence OR adhered OR nonadherence OR persist OR persistance OR per-
sisted OR compliance OR comply OR complied OR noncompliance OR concordance OR
nonconcordance OR cooperative OR cooperation OR cooperate OR cooperated OR unco-









CONDITION/ DISEASE: cystic fibrosis OR mucoviscidosis OR mucoviscidose
OTHER TERMS: adhere OR adherence OR adhered OR nonadherence OR persist OR persis-
tance OR persisted OR compliance OR comply OR complied OR noncompliance OR con-
cordance OR nonconcordance OR cooperative OR cooperation OR cooperate OR cooper-
ated OR uncooperative OR conform




(cystic fibrosis OR mucoviscidosis OR mucoviscidose) AND (adhere OR adherence OR ad-
hered OR nonadherence OR persist OR persistance OR persisted OR compliance OR com-
ply OR complied OR noncompliance OR concordance OR nonconcordance OR coopera-








cystic fibrosis OR mucoviscidosis OR mucoviscidose
  (Continued)
 
Appendix 2. Example summary of findings table
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Interventions to improve adherence to airway clearance treatment compared to no treatment or usual care for people with
cystic fibrosis
Patient or population: people with cystic fibrosis
Settings: hospital or community
Intervention: interventions to improve adherence to airway clearance treatment
Comparison: no treatment or usual care
Illustrative compara-



























           
Frequency of hospitalisation
Follow-up: medium terma
           
Frequency of non-hospitalised respiratory infec-
tion
Follow-up: medium terma
           
Exercise capacity (change from baseline)
Follow-up: medium terma
           
QoL (change from baseline)
(using a disease-specific tool or a non-specific tool)
Follow-up: medium terma
           
FEV1 % predicted (change from baseline)
Follow-up: medium terma
           
FVC % predicted (change from baseline)
Follow-up: medium terma
           
*The basis of the assumed risk and the corresponding risk is described in the comments. For lung function outcomes, absolute data
was not presented in a format which could be analysed due to the crossover design of the study, therefore only analyses of percent-
age change from baseline were included in this review
Abbreviations: CI: confidence interval; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; QoL: quality of life.
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Footnotes: a medium term is over one month and up to six months
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: we are very uncertain about the estimate.
  (Continued)
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